A systematic review of the cost and cost‐effectiveness studies of proton radiotherapy

CONCLUSIONSWith greatly limited amounts of data, PBT offers promising cost‐effectiveness for pediatric brain tumors, well‐selected breast cancers, locoregionally advanced NSCLC, and high‐risk head/neck cancers. Heretofore, it has not been demonstrated that PBT is cost‐effective for prostate cancer or early stage NSCLC. Careful patient selection is absolutely critical to assess cost‐effectiveness. Together with increasing PBT availability, clinical trial evidence, and ongoing major technological improvements, cost‐effectiveness data and conclusions from this analysis could change rapidly. Cancer 2016. © 2016 American Cancer Society.
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Review Article Source Type: research